Bac115: A Novel Lantibiotic from Staphylococcus epidermidis ID: 2012-057

Bac115 represents a groundbreaking discovery in the fight against gram-positive bacterial infections, offering a new, potent antimicrobial solution.

Technology Overview

Bac115 is a newly discovered lantibiotic produced by Staphylococcus epidermidis strain 115, showing broad-spectrum antimicrobial activity against various gram-positive pathogens, including strains resistant to conventional antibiotics. Its unique mode of action and genetic encoding present a significant advancement in antibiotic development.

Key Advantages

• Broad-spectrum efficacy against gram-positive bacteria, including drug-resistant strains
• Potential application against acid-fast bacteria like Mycobacterium
• Encoded on a high molecular weight plasmid, facilitating genetic manipulation and study
• Represents a novel structural class of lantibiotics, promising unique mechanisms of action
• Can be efficiently extracted and purified for research and therapeutic use

Problems Addressed

• Antibiotic resistance in clinically significant gram-positive bacteria
• Limited availability of new antibiotics with novel mechanisms of action
• Challenges in treating infections caused by acid-fast bacteria

Market Applications

• New antibiotic formulations for healthcare and pharmaceutical industries
• Development of topical and systemic treatments for bacterial infections
• Research tool in microbiology and antibiotic resistance studies
• Potential use in biotechnology for the production of antimicrobial materials

Additional Information

Technology ID: 2012-057
Sell Sheet: Download the Sell Sheet here
Market Analysis: Contact us for a more in-depth market report
Date Published: 30 June, 2025